

Global Bladder Cancer Biologics Market Growth 2024-2030

https://marketpublishers.com/r/GCBCEDD1E736EN.html

Date: July 2024

Pages: 111

Price: US\$ 3,660.00 (Single User License)

ID: GCBCEDD1E736EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Bladder Cancer Biologics market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) 'newest research report, the "Bladder Cancer Biologics Industry Forecast" looks at past sales and reviews total world Bladder Cancer Biologics sales in 2023, providing a comprehensive analysis by region and market sector of projected Bladder Cancer Biologics sales for 2024 through 2030. With Bladder Cancer Biologics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Bladder Cancer Biologics industry.

This Insight Report provides a comprehensive analysis of the global Bladder Cancer Biologics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bladder Cancer Biologics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bladder Cancer Biologics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bladder Cancer Biologics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up



qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bladder Cancer Biologics.

United States market for Bladder Cancer Biologics is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Bladder Cancer Biologics is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Bladder Cancer Biologics is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Bladder Cancer Biologics players cover AstraZenenca, Bristol-Myers Squibb Company, Chugai Pharmaceutical, Cold Genesys, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Bladder Cancer Biologics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

PD-1 Inhibitors

CTLA-4 Inhibitors

FGFR Inhibitors

Others

Segmentation by Application:

Hospital

Specialty Clinic




Other

Th

nis report also splits the market by region:		
Americas		
	United States	
	Canada	
	Mexico	
	Brazil	
APAC		
	China	
	Japan	
	Korea	
	Southeast Asia	
	India	
	Australia	
Europe		
	Germany	
	France	
	UK	

Italy







Roche Holding

Spectrum Pharmaceuticals

Taiho Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bladder Cancer Biologics market?

What factors are driving Bladder Cancer Biologics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bladder Cancer Biologics market opportunities vary by end market size?

How does Bladder Cancer Biologics break out by Type, by Application?



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Bladder Cancer Biologics Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Bladder Cancer Biologics by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Bladder Cancer Biologics by Country/Region, 2019, 2023 & 2030
- 2.2 Bladder Cancer Biologics Segment by Type
 - 2.2.1 PD-1 Inhibitors
 - 2.2.2 CTLA-4 Inhibitors
 - 2.2.3 FGFR Inhibitors
 - 2.2.4 Others
- 2.3 Bladder Cancer Biologics Sales by Type
 - 2.3.1 Global Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
- 2.3.2 Global Bladder Cancer Biologics Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Bladder Cancer Biologics Sale Price by Type (2019-2024)
- 2.4 Bladder Cancer Biologics Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Specialty Clinic
 - 2.4.3 Other
- 2.5 Bladder Cancer Biologics Sales by Application
 - 2.5.1 Global Bladder Cancer Biologics Sale Market Share by Application (2019-2024)
- 2.5.2 Global Bladder Cancer Biologics Revenue and Market Share by Application (2019-2024)



2.5.3 Global Bladder Cancer Biologics Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

- 3.1 Global Bladder Cancer Biologics Breakdown Data by Company
 - 3.1.1 Global Bladder Cancer Biologics Annual Sales by Company (2019-2024)
 - 3.1.2 Global Bladder Cancer Biologics Sales Market Share by Company (2019-2024)
- 3.2 Global Bladder Cancer Biologics Annual Revenue by Company (2019-2024)
 - 3.2.1 Global Bladder Cancer Biologics Revenue by Company (2019-2024)
- 3.2.2 Global Bladder Cancer Biologics Revenue Market Share by Company (2019-2024)
- 3.3 Global Bladder Cancer Biologics Sale Price by Company
- 3.4 Key Manufacturers Bladder Cancer Biologics Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Bladder Cancer Biologics Product Location Distribution
- 3.4.2 Players Bladder Cancer Biologics Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BLADDER CANCER BIOLOGICS BY GEOGRAPHIC REGION

- 4.1 World Historic Bladder Cancer Biologics Market Size by Geographic Region (2019-2024)
- 4.1.1 Global Bladder Cancer Biologics Annual Sales by Geographic Region (2019-2024)
- 4.1.2 Global Bladder Cancer Biologics Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Bladder Cancer Biologics Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Bladder Cancer Biologics Annual Sales by Country/Region (2019-2024)
- 4.2.2 Global Bladder Cancer Biologics Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Bladder Cancer Biologics Sales Growth
- 4.4 APAC Bladder Cancer Biologics Sales Growth
- 4.5 Europe Bladder Cancer Biologics Sales Growth



4.6 Middle East & Africa Bladder Cancer Biologics Sales Growth

5 AMERICAS

- 5.1 Americas Bladder Cancer Biologics Sales by Country
 - 5.1.1 Americas Bladder Cancer Biologics Sales by Country (2019-2024)
- 5.1.2 Americas Bladder Cancer Biologics Revenue by Country (2019-2024)
- 5.2 Americas Bladder Cancer Biologics Sales by Type (2019-2024)
- 5.3 Americas Bladder Cancer Biologics Sales by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Bladder Cancer Biologics Sales by Region
 - 6.1.1 APAC Bladder Cancer Biologics Sales by Region (2019-2024)
 - 6.1.2 APAC Bladder Cancer Biologics Revenue by Region (2019-2024)
- 6.2 APAC Bladder Cancer Biologics Sales by Type (2019-2024)
- 6.3 APAC Bladder Cancer Biologics Sales by Application (2019-2024)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Bladder Cancer Biologics by Country
- 7.1.1 Europe Bladder Cancer Biologics Sales by Country (2019-2024)
- 7.1.2 Europe Bladder Cancer Biologics Revenue by Country (2019-2024)
- 7.2 Europe Bladder Cancer Biologics Sales by Type (2019-2024)
- 7.3 Europe Bladder Cancer Biologics Sales by Application (2019-2024)
- 7.4 Germany
- 7.5 France
- 7.6 UK



- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Bladder Cancer Biologics by Country
 - 8.1.1 Middle East & Africa Bladder Cancer Biologics Sales by Country (2019-2024)
 - 8.1.2 Middle East & Africa Bladder Cancer Biologics Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Bladder Cancer Biologics Sales by Type (2019-2024)
- 8.3 Middle East & Africa Bladder Cancer Biologics Sales by Application (2019-2024)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Bladder Cancer Biologics
- 10.3 Manufacturing Process Analysis of Bladder Cancer Biologics
- 10.4 Industry Chain Structure of Bladder Cancer Biologics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Bladder Cancer Biologics Distributors
- 11.3 Bladder Cancer Biologics Customer

12 WORLD FORECAST REVIEW FOR BLADDER CANCER BIOLOGICS BY GEOGRAPHIC REGION



- 12.1 Global Bladder Cancer Biologics Market Size Forecast by Region
 - 12.1.1 Global Bladder Cancer Biologics Forecast by Region (2025-2030)
- 12.1.2 Global Bladder Cancer Biologics Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Bladder Cancer Biologics Forecast by Type (2025-2030)
- 12.7 Global Bladder Cancer Biologics Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

- 13.1 AstraZenenca
 - 13.1.1 AstraZenenca Company Information
 - 13.1.2 AstraZenenca Bladder Cancer Biologics Product Portfolios and Specifications
- 13.1.3 AstraZenenca Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.1.4 AstraZenenca Main Business Overview
 - 13.1.5 AstraZenenca Latest Developments
- 13.2 Bristol-Myers Squibb Company
 - 13.2.1 Bristol-Myers Squibb Company Company Information
- 13.2.2 Bristol-Myers Squibb Company Bladder Cancer Biologics Product Portfolios and Specifications
- 13.2.3 Bristol-Myers Squibb Company Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.2.4 Bristol-Myers Squibb Company Main Business Overview
 - 13.2.5 Bristol-Myers Squibb Company Latest Developments
- 13.3 Chugai Pharmaceutical
 - 13.3.1 Chugai Pharmaceutical Company Information
- 13.3.2 Chugai Pharmaceutical Bladder Cancer Biologics Product Portfolios and Specifications
- 13.3.3 Chugai Pharmaceutical Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.3.4 Chugai Pharmaceutical Main Business Overview
 - 13.3.5 Chugai Pharmaceutical Latest Developments
- 13.4 Cold Genesys
 - 13.4.1 Cold Genesys Company Information



- 13.4.2 Cold Genesys Bladder Cancer Biologics Product Portfolios and Specifications
- 13.4.3 Cold Genesys Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 Cold Genesys Main Business Overview
 - 13.4.5 Cold Genesys Latest Developments
- 13.5 Eli Lilly
 - 13.5.1 Eli Lilly Company Information
 - 13.5.2 Eli Lilly Bladder Cancer Biologics Product Portfolios and Specifications
- 13.5.3 Eli Lilly Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Eli Lilly Main Business Overview
 - 13.5.5 Eli Lilly Latest Developments
- 13.6 Nighthawk Biosciences
 - 13.6.1 Nighthawk Biosciences Company Information
- 13.6.2 Nighthawk Biosciences Bladder Cancer Biologics Product Portfolios and Specifications
- 13.6.3 Nighthawk Biosciences Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Nighthawk Biosciences Main Business Overview
 - 13.6.5 Nighthawk Biosciences Latest Developments
- 13.7 Merck & Co
 - 13.7.1 Merck & Co Company Information
 - 13.7.2 Merck & Co Bladder Cancer Biologics Product Portfolios and Specifications
- 13.7.3 Merck & Co Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Merck & Co Main Business Overview
 - 13.7.5 Merck & Co Latest Developments
- 13.8 Mirati Therapeutics
 - 13.8.1 Mirati Therapeutics Company Information
- 13.8.2 Mirati Therapeutics Bladder Cancer Biologics Product Portfolios and Specifications
- 13.8.3 Mirati Therapeutics Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 Mirati Therapeutics Main Business Overview
 - 13.8.5 Mirati Therapeutics Latest Developments
- 13.9 OncoGenex
 - 13.9.1 OncoGenex Company Information
 - 13.9.2 OncoGenex Bladder Cancer Biologics Product Portfolios and Specifications
- 13.9.3 OncoGenex Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin



(2019-2024)

- 13.9.4 OncoGenex Main Business Overview
- 13.9.5 OncoGenex Latest Developments
- 13.10 Pfizer
 - 13.10.1 Pfizer Company Information
 - 13.10.2 Pfizer Bladder Cancer Biologics Product Portfolios and Specifications
- 13.10.3 Pfizer Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.10.4 Pfizer Main Business Overview
 - 13.10.5 Pfizer Latest Developments
- 13.11 Roche Holding
 - 13.11.1 Roche Holding Company Information
 - 13.11.2 Roche Holding Bladder Cancer Biologics Product Portfolios and Specifications
- 13.11.3 Roche Holding Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.11.4 Roche Holding Main Business Overview
 - 13.11.5 Roche Holding Latest Developments
- 13.12 Spectrum Pharmaceuticals
 - 13.12.1 Spectrum Pharmaceuticals Company Information
- 13.12.2 Spectrum Pharmaceuticals Bladder Cancer Biologics Product Portfolios and Specifications
- 13.12.3 Spectrum Pharmaceuticals Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.12.4 Spectrum Pharmaceuticals Main Business Overview
 - 13.12.5 Spectrum Pharmaceuticals Latest Developments
- 13.13 Taiho Pharmaceutical
 - 13.13.1 Taiho Pharmaceutical Company Information
- 13.13.2 Taiho Pharmaceutical Bladder Cancer Biologics Product Portfolios and Specifications
- 13.13.3 Taiho Pharmaceutical Bladder Cancer Biologics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.13.4 Taiho Pharmaceutical Main Business Overview
 - 13.13.5 Taiho Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

- Table 1. Bladder Cancer Biologics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Bladder Cancer Biologics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of PD-1 Inhibitors
- Table 4. Major Players of CTLA-4 Inhibitors
- Table 5. Major Players of FGFR Inhibitors
- Table 6. Major Players of Others
- Table 7. Global Bladder Cancer Biologics Sales by Type (2019-2024) & (K Units)
- Table 8. Global Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
- Table 9. Global Bladder Cancer Biologics Revenue by Type (2019-2024) & (\$ million)
- Table 10. Global Bladder Cancer Biologics Revenue Market Share by Type (2019-2024)
- Table 11. Global Bladder Cancer Biologics Sale Price by Type (2019-2024) & (US\$/Unit)
- Table 12. Global Bladder Cancer Biologics Sale by Application (2019-2024) & (K Units)
- Table 13. Global Bladder Cancer Biologics Sale Market Share by Application (2019-2024)
- Table 14. Global Bladder Cancer Biologics Revenue by Application (2019-2024) & (\$million)
- Table 15. Global Bladder Cancer Biologics Revenue Market Share by Application (2019-2024)
- Table 16. Global Bladder Cancer Biologics Sale Price by Application (2019-2024) & (US\$/Unit)
- Table 17. Global Bladder Cancer Biologics Sales by Company (2019-2024) & (K Units)
- Table 18. Global Bladder Cancer Biologics Sales Market Share by Company (2019-2024)
- Table 19. Global Bladder Cancer Biologics Revenue by Company (2019-2024) & (\$ millions)
- Table 20. Global Bladder Cancer Biologics Revenue Market Share by Company (2019-2024)
- Table 21. Global Bladder Cancer Biologics Sale Price by Company (2019-2024) & (US\$/Unit)
- Table 22. Key Manufacturers Bladder Cancer Biologics Producing Area Distribution and Sales Area
- Table 23. Players Bladder Cancer Biologics Products Offered



- Table 24. Bladder Cancer Biologics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- Table 25. New Products and Potential Entrants
- Table 26. Market M&A Activity & Strategy
- Table 27. Global Bladder Cancer Biologics Sales by Geographic Region (2019-2024) & (K Units)
- Table 28. Global Bladder Cancer Biologics Sales Market Share Geographic Region (2019-2024)
- Table 29. Global Bladder Cancer Biologics Revenue by Geographic Region (2019-2024) & (\$ millions)
- Table 30. Global Bladder Cancer Biologics Revenue Market Share by Geographic Region (2019-2024)
- Table 31. Global Bladder Cancer Biologics Sales by Country/Region (2019-2024) & (K Units)
- Table 32. Global Bladder Cancer Biologics Sales Market Share by Country/Region (2019-2024)
- Table 33. Global Bladder Cancer Biologics Revenue by Country/Region (2019-2024) & (\$ millions)
- Table 34. Global Bladder Cancer Biologics Revenue Market Share by Country/Region (2019-2024)
- Table 35. Americas Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)
- Table 36. Americas Bladder Cancer Biologics Sales Market Share by Country (2019-2024)
- Table 37. Americas Bladder Cancer Biologics Revenue by Country (2019-2024) & (\$ millions)
- Table 38. Americas Bladder Cancer Biologics Sales by Type (2019-2024) & (K Units)
- Table 39. Americas Bladder Cancer Biologics Sales by Application (2019-2024) & (K Units)
- Table 40. APAC Bladder Cancer Biologics Sales by Region (2019-2024) & (K Units)
- Table 41. APAC Bladder Cancer Biologics Sales Market Share by Region (2019-2024)
- Table 42. APAC Bladder Cancer Biologics Revenue by Region (2019-2024) & (\$ millions)
- Table 43. APAC Bladder Cancer Biologics Sales by Type (2019-2024) & (K Units)
- Table 44. APAC Bladder Cancer Biologics Sales by Application (2019-2024) & (K Units)
- Table 45. Europe Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)
- Table 46. Europe Bladder Cancer Biologics Revenue by Country (2019-2024) & (\$ millions)
- Table 47. Europe Bladder Cancer Biologics Sales by Type (2019-2024) & (K Units)
- Table 48. Europe Bladder Cancer Biologics Sales by Application (2019-2024) & (K



Units)

Table 49. Middle East & Africa Bladder Cancer Biologics Sales by Country (2019-2024) & (K Units)

Table 50. Middle East & Africa Bladder Cancer Biologics Revenue Market Share by Country (2019-2024)

Table 51. Middle East & Africa Bladder Cancer Biologics Sales by Type (2019-2024) & (K Units)

Table 52. Middle East & Africa Bladder Cancer Biologics Sales by Application (2019-2024) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Bladder Cancer Biologics

Table 54. Key Market Challenges & Risks of Bladder Cancer Biologics

Table 55. Key Industry Trends of Bladder Cancer Biologics

Table 56. Bladder Cancer Biologics Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Bladder Cancer Biologics Distributors List

Table 59. Bladder Cancer Biologics Customer List

Table 60. Global Bladder Cancer Biologics Sales Forecast by Region (2025-2030) & (K Units)

Table 61. Global Bladder Cancer Biologics Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 62. Americas Bladder Cancer Biologics Sales Forecast by Country (2025-2030) & (K Units)

Table 63. Americas Bladder Cancer Biologics Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 64. APAC Bladder Cancer Biologics Sales Forecast by Region (2025-2030) & (K Units)

Table 65. APAC Bladder Cancer Biologics Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 66. Europe Bladder Cancer Biologics Sales Forecast by Country (2025-2030) & (K Units)

Table 67. Europe Bladder Cancer Biologics Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. Middle East & Africa Bladder Cancer Biologics Sales Forecast by Country (2025-2030) & (K Units)

Table 69. Middle East & Africa Bladder Cancer Biologics Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 70. Global Bladder Cancer Biologics Sales Forecast by Type (2025-2030) & (K Units)

Table 71. Global Bladder Cancer Biologics Revenue Forecast by Type (2025-2030) & (\$



millions)

Table 72. Global Bladder Cancer Biologics Sales Forecast by Application (2025-2030) & (K Units)

Table 73. Global Bladder Cancer Biologics Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 74. AstraZenenca Basic Information, Bladder Cancer Biologics Manufacturing Base, Sales Area and Its Competitors

Table 75. AstraZenenca Bladder Cancer Biologics Product Portfolios and Specifications

Table 76. AstraZenenca Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2019-2024)

Table 77. AstraZenenca Main Business

Table 78. AstraZenenca Latest Developments

Table 79. Bristol-Myers Squibb Company Basic Information, Bladder Cancer Biologics Manufacturing Base, Sales Area and Its Competitors

Table 80. Bristol-Myers Squibb Company Bladder Cancer Biologics Product Portfolios and Specifications

Table 81. Bristol-Myers Squibb Company Bladder Cancer Biologics Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 82. Bristol-Myers Squibb Company Main Business

Table 83. Bristol-Myers Squibb Company Latest Developments

Table 84. Chugai Pharmaceutical Basic Information, Bladder Cancer Biologics

Manufacturing Base, Sales Area and Its Competitors

Table 85. Chugai Pharmaceutical Bladder Cancer Biologics Product Portfolios and Specifications

Table 86. Chugai Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 87. Chugai Pharmaceutical Main Business

Table 88. Chugai Pharmaceutical Latest Developments

Table 89. Cold Genesys Basic Information, Bladder Cancer Biologics Manufacturing

Base, Sales Area and Its Competitors

Table 90. Cold Genesys Bladder Cancer Biologics Product Portfolios and Specifications

Table 91. Cold Genesys Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2019-2024)

Table 92. Cold Genesys Main Business

Table 93. Cold Genesys Latest Developments

Table 94. Eli Lilly Basic Information, Bladder Cancer Biologics Manufacturing Base,

Sales Area and Its Competitors

Table 95. Eli Lilly Bladder Cancer Biologics Product Portfolios and Specifications

Table 96. Eli Lilly Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million), Price



(US\$/Unit) and Gross Margin (2019-2024)

Table 97. Eli Lilly Main Business

Table 98. Eli Lilly Latest Developments

Table 99. Nighthawk Biosciences Basic Information, Bladder Cancer Biologics

Manufacturing Base, Sales Area and Its Competitors

Table 100. Nighthawk Biosciences Bladder Cancer Biologics Product Portfolios and Specifications

Table 101. Nighthawk Biosciences Bladder Cancer Biologics Sales (K Units), Revenue

(\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 102. Nighthawk Biosciences Main Business

Table 103. Nighthawk Biosciences Latest Developments

Table 104. Merck & Co Basic Information, Bladder Cancer Biologics Manufacturing

Base, Sales Area and Its Competitors

Table 105. Merck & Co Bladder Cancer Biologics Product Portfolios and Specifications

Table 106. Merck & Co Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2019-2024)

Table 107. Merck & Co Main Business

Table 108. Merck & Co Latest Developments

Table 109. Mirati Therapeutics Basic Information, Bladder Cancer Biologics

Manufacturing Base, Sales Area and Its Competitors

Table 110. Mirati Therapeutics Bladder Cancer Biologics Product Portfolios and Specifications

Table 111. Mirati Therapeutics Bladder Cancer Biologics Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 112. Mirati Therapeutics Main Business

Table 113. Mirati Therapeutics Latest Developments

Table 114. OncoGenex Basic Information, Bladder Cancer Biologics Manufacturing

Base, Sales Area and Its Competitors

Table 115. OncoGenex Bladder Cancer Biologics Product Portfolios and Specifications

Table 116. OncoGenex Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2019-2024)

Table 117. OncoGenex Main Business

Table 118. OncoGenex Latest Developments

Table 119. Pfizer Basic Information, Bladder Cancer Biologics Manufacturing Base,

Sales Area and Its Competitors

Table 120. Pfizer Bladder Cancer Biologics Product Portfolios and Specifications

Table 121. Pfizer Bladder Cancer Biologics Sales (K Units), Revenue (\$ Million), Price

(US\$/Unit) and Gross Margin (2019-2024)

Table 122. Pfizer Main Business



Table 123. Pfizer Latest Developments

Table 124. Roche Holding Basic Information, Bladder Cancer Biologics Manufacturing

Base, Sales Area and Its Competitors

Table 125. Roche Holding Bladder Cancer Biologics Product Portfolios and Specifications

Table 126. Roche Holding Bladder Cancer Biologics Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 127. Roche Holding Main Business

Table 128. Roche Holding Latest Developments

Table 129. Spectrum Pharmaceuticals Basic Information, Bladder Cancer Biologics

Manufacturing Base, Sales Area and Its Competitors

Table 130. Spectrum Pharmaceuticals Bladder Cancer Biologics Product Portfolios and Specifications

Table 131. Spectrum Pharmaceuticals Bladder Cancer Biologics Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 132. Spectrum Pharmaceuticals Main Business

Table 133. Spectrum Pharmaceuticals Latest Developments

Table 134. Taiho Pharmaceutical Basic Information, Bladder Cancer Biologics

Manufacturing Base, Sales Area and Its Competitors

Table 135. Taiho Pharmaceutical Bladder Cancer Biologics Product Portfolios and Specifications

Table 136. Taiho Pharmaceutical Bladder Cancer Biologics Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 137. Taiho Pharmaceutical Main Business

Table 138. Taiho Pharmaceutical Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Bladder Cancer Biologics
- Figure 2. Bladder Cancer Biologics Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Bladder Cancer Biologics Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Bladder Cancer Biologics Revenue Growth Rate 2019-2030 (\$ millions)
- Figure 8. Bladder Cancer Biologics Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Figure 9. Bladder Cancer Biologics Sales Market Share by Country/Region (2023)
- Figure 10. Bladder Cancer Biologics Sales Market Share by Country/Region (2019, 2023 & 2030)
- Figure 11. Product Picture of PD-1 Inhibitors
- Figure 12. Product Picture of CTLA-4 Inhibitors
- Figure 13. Product Picture of FGFR Inhibitors
- Figure 14. Product Picture of Others
- Figure 15. Global Bladder Cancer Biologics Sales Market Share by Type in 2023
- Figure 16. Global Bladder Cancer Biologics Revenue Market Share by Type (2019-2024)
- Figure 17. Bladder Cancer Biologics Consumed in Hospital
- Figure 18. Global Bladder Cancer Biologics Market: Hospital (2019-2024) & (K Units)
- Figure 19. Bladder Cancer Biologics Consumed in Specialty Clinic
- Figure 20. Global Bladder Cancer Biologics Market: Specialty Clinic (2019-2024) & (K Units)
- Figure 21. Bladder Cancer Biologics Consumed in Other
- Figure 22. Global Bladder Cancer Biologics Market: Other (2019-2024) & (K Units)
- Figure 23. Global Bladder Cancer Biologics Sale Market Share by Application (2023)
- Figure 24. Global Bladder Cancer Biologics Revenue Market Share by Application in 2023
- Figure 25. Bladder Cancer Biologics Sales by Company in 2023 (K Units)
- Figure 26. Global Bladder Cancer Biologics Sales Market Share by Company in 2023
- Figure 27. Bladder Cancer Biologics Revenue by Company in 2023 (\$ millions)
- Figure 28. Global Bladder Cancer Biologics Revenue Market Share by Company in 2023
- Figure 29. Global Bladder Cancer Biologics Sales Market Share by Geographic Region



(2019-2024)

- Figure 30. Global Bladder Cancer Biologics Revenue Market Share by Geographic Region in 2023
- Figure 31. Americas Bladder Cancer Biologics Sales 2019-2024 (K Units)
- Figure 32. Americas Bladder Cancer Biologics Revenue 2019-2024 (\$ millions)
- Figure 33. APAC Bladder Cancer Biologics Sales 2019-2024 (K Units)
- Figure 34. APAC Bladder Cancer Biologics Revenue 2019-2024 (\$ millions)
- Figure 35. Europe Bladder Cancer Biologics Sales 2019-2024 (K Units)
- Figure 36. Europe Bladder Cancer Biologics Revenue 2019-2024 (\$ millions)
- Figure 37. Middle East & Africa Bladder Cancer Biologics Sales 2019-2024 (K Units)
- Figure 38. Middle East & Africa Bladder Cancer Biologics Revenue 2019-2024 (\$ millions)
- Figure 39. Americas Bladder Cancer Biologics Sales Market Share by Country in 2023
- Figure 40. Americas Bladder Cancer Biologics Revenue Market Share by Country (2019-2024)
- Figure 41. Americas Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
- Figure 42. Americas Bladder Cancer Biologics Sales Market Share by Application (2019-2024)
- Figure 43. United States Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 44. Canada Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 45. Mexico Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 46. Brazil Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 47. APAC Bladder Cancer Biologics Sales Market Share by Region in 2023
- Figure 48. APAC Bladder Cancer Biologics Revenue Market Share by Region (2019-2024)
- Figure 49. APAC Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
- Figure 50. APAC Bladder Cancer Biologics Sales Market Share by Application (2019-2024)
- Figure 51. China Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 52. Japan Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 53. South Korea Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 54. Southeast Asia Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 55. India Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 56. Australia Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 57. China Taiwan Bladder Cancer Biologics Revenue Growth 2019-2024 (\$



millions)

- Figure 58. Europe Bladder Cancer Biologics Sales Market Share by Country in 2023
- Figure 59. Europe Bladder Cancer Biologics Revenue Market Share by Country (2019-2024)
- Figure 60. Europe Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
- Figure 61. Europe Bladder Cancer Biologics Sales Market Share by Application (2019-2024)
- Figure 62. Germany Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 63. France Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 64. UK Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 65. Italy Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 66. Russia Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 67. Middle East & Africa Bladder Cancer Biologics Sales Market Share by Country (2019-2024)
- Figure 68. Middle East & Africa Bladder Cancer Biologics Sales Market Share by Type (2019-2024)
- Figure 69. Middle East & Africa Bladder Cancer Biologics Sales Market Share by Application (2019-2024)
- Figure 70. Egypt Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 71. South Africa Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 72. Israel Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 73. Turkey Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 74. GCC Countries Bladder Cancer Biologics Revenue Growth 2019-2024 (\$ millions)
- Figure 75. Manufacturing Cost Structure Analysis of Bladder Cancer Biologics in 2023
- Figure 76. Manufacturing Process Analysis of Bladder Cancer Biologics
- Figure 77. Industry Chain Structure of Bladder Cancer Biologics
- Figure 78. Channels of Distribution
- Figure 79. Global Bladder Cancer Biologics Sales Market Forecast by Region (2025-2030)
- Figure 80. Global Bladder Cancer Biologics Revenue Market Share Forecast by Region (2025-2030)
- Figure 81. Global Bladder Cancer Biologics Sales Market Share Forecast by Type (2025-2030)
- Figure 82. Global Bladder Cancer Biologics Revenue Market Share Forecast by Type (2025-2030)
- Figure 83. Global Bladder Cancer Biologics Sales Market Share Forecast by Application (2025-2030)



Figure 84. Global Bladder Cancer Biologics Revenue Market Share Forecast by Application (2025-2030)



I would like to order

Product name: Global Bladder Cancer Biologics Market Growth 2024-2030 Product link: https://marketpublishers.com/r/GCBCEDD1E736EN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GCBCEDD1E736EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms